The agreement strengthens Elaris’ IP position and supports the advancement of its lead vaccine program, which aims to broaden protection against C. difficile infection through additional proprietary components. With no approved prophylactic vaccine currently available for CDI, the program addresses a major unmet medical need. Elaris plans to advance the candidate through IND-enabling development, with the goal of initiating clinical studies around 2027.
Read the full press release here
The website uses cookies to ensure you get the best experience on our website.
Anonymous evaluation for troubleshooting and further development
Purpose: error analysis, statistical evaluation of our website accesses, campaign analysis, conversion tracking, retargeting
Processing operations: Collection of access data, data from your browser and data about the content accessed; Execution of analysis software and storage of data on your terminal device, anonymization of the data collected; Evaluation of the anonymous data in the form of statistics
Storage period: data on your device for up to two years.
Joint controller: Google Ireland Limited, Gordon House, Barrow Street, Dublin 4, Ireland Legal basis for data processing: voluntary, consent that can be revoked at any time Consequences of non-consent: No direct impact on the functionality of the website; however limited opportunities for further development and error analysis
Data transfer to the USA: Your data is processed by the provider Google in the USA, which involves corresponding risks, e.g. B. a secret data access by US authorities. With your consent, you also consent to the processing of your data in the USA.
